Brokerages Set EIKN (NASDAQ:EIKN) Price Target at $25.60

EIKN (NASDAQ:EIKN) has been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $25.60.

A number of research firms recently commented on EIKN. JPMorgan Chase & Co. assumed coverage on EIKN in a research report on Monday, March 2nd. They set an “overweight” rating and a $29.00 price target on the stock. Mizuho assumed coverage on EIKN in a research report on Monday, March 2nd. They issued an “outperform” rating and a $26.00 price objective for the company. Zacks Research raised EIKN to a “hold” rating in a research note on Friday, February 27th. Cantor Fitzgerald began coverage on EIKN in a report on Monday, March 2nd. They set an “overweight” rating on the stock. Finally, Morgan Stanley began coverage on EIKN in a research note on Monday, March 2nd. They issued an “overweight” rating and a $32.00 target price for the company.

EIKN Trading Down 1.1%

NASDAQ EIKN opened at $14.38 on Monday. EIKN has a 1-year low of $13.28 and a 1-year high of $17.40.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.